Swain, Sandra M.; Miles, David; Kim, Sung Bae; Im, Young-Hyuck; Im, Seock-Ah; Semiglazov, Vladimir; Ciruelos, Eva M.; Schneeweiss, Andreas; Loi, Sherene; Monturus, Estefanía; Clark, Emma; Knott, Adam; Restuccia, Eleonora; Benyunes, Mark C.; Cortés, Javier; Andrade, Jurandyr Moreira de 
Source: The Lancet Oncology. Unidade: FMRP
Subjects: ANTICORPOS MONOCLONAIS, PROTOCOLOS CLÍNICOS, QUIMIOTERAPIA COMBINADA, ANTINEOPLÁSICOS, NEOPLASIAS MAMÁRIAS, MÉTODO DUPLO-CEGO, METÁSTASE NEOPLÁSICA, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SWAIN, Sandra M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology, v. 21, n. 4, p. 519-530, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(19)30863-0. Acesso em: 09 jun. 2024.APA
Swain, S. M., Miles, D., Kim, S. B., Im, Y. -H., Im, S. -A., Semiglazov, V., et al. (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology, 21( 4), 519-530. doi:10.1016/S1470-2045(19)30863-0NLM
Swain SM, Miles D, Kim SB, Im Y-H, Im S-A, Semiglazov V, Ciruelos EM, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, Andrade JM de. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [Internet]. The Lancet Oncology. 2020 ; 21( 4): 519-530.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/S1470-2045(19)30863-0Vancouver
Swain SM, Miles D, Kim SB, Im Y-H, Im S-A, Semiglazov V, Ciruelos EM, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, Andrade JM de. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [Internet]. The Lancet Oncology. 2020 ; 21( 4): 519-530.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/S1470-2045(19)30863-0
